Literature DB >> 30692860

Multiple Sclerosis Functional Composite.

Serkan Demir1.   

Abstract

Functional disorders due to multiple sclerosis are evaluated using rating scales. EDSS is a scant which is very inadequate in evaluating cognitive functions, is significantly limited in evaluating upper extremity functions and is highly difficult to repeat. Multiple Sclerosis Functional Composite (MSFC) is considered as a test that has been proposed in recent years in MS clinical trials and can overcome these negative features of EDSS. Three primary assessment methods were suggested for MSFC (9): 1) 25-step walking, 2) 9-Hole Peg test (9-HPT), and 3) Paced Auditory Serial Addition Test-3 (PASAT-3).

Entities:  

Keywords:  Multiple sclerosis; expanded disability status scale; multiple sclerosis functional composite

Year:  2018        PMID: 30692860      PMCID: PMC6278630          DOI: 10.29399/npa.23349

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  22 in total

Review 1.  The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

Authors:  J S Fischer; R A Rudick; G R Cutter; S C Reingold
Journal:  Mult Scler       Date:  1999-08       Impact factor: 6.312

2.  Adult norms for a commercially available Nine Hole Peg Test for finger dexterity.

Authors:  Kimatha Oxford Grice; Kimberly A Vogel; Viet Le; Ana Mitchell; Sonia Muniz; Mary Ann Vollmer
Journal:  Am J Occup Ther       Date:  2003 Sep-Oct

Review 3.  A comprehensive review of the Paced Auditory Serial Addition Test (PASAT).

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2005-11-14       Impact factor: 2.813

4.  Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Authors:  J A Cohen; G R Cutter; J S Fischer; A D Goodman; F R Heidenreich; A J Jak; J E Kniker; M F Kooijmans; J M Lull; A W Sandrock; J H Simon; N A Simonian; J N Whitaker
Journal:  Arch Neurol       Date:  2001-06

5.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

6.  Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Authors:  R A Rudick; G Cutter; M Baier; E Fisher; D Dougherty; B Weinstock-Guttman; M K Mass; D Miller; N A Simonian
Journal:  Neurology       Date:  2001-05-22       Impact factor: 9.910

7.  The Paced Auditory Serial Addition Test: to what extent is it performed as instructed, and is it associated with disease course?

Authors:  H Coo; W M Hopman; C M Edgar; E V McBride; D G Brunet
Journal:  Mult Scler       Date:  2005-02       Impact factor: 6.312

8.  Intrarater and interrater reliability of the MS functional composite outcome measure.

Authors:  J A Cohen; J S Fischer; D M Bolibrush; A J Jak; J E Kniker; L A Mertz; T T Skaramagas; G R Cutter
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

9.  Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.

Authors:  Serkan Ozakbas; Inanc Cagiran; Burcu Ormeci; Egemen Idiman
Journal:  J Neurol Sci       Date:  2004-03-15       Impact factor: 3.181

Review 10.  Temporal trends in the incidence of multiple sclerosis: a systematic review.

Authors:  Alvaro Alonso; Miguel A Hernán
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

View more
  3 in total

1.  Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Multiple Sclerosis. A Pilot Study.

Authors:  María Benlloch; María Cuerda Ballester; Eraci Drehmer; Jose Luis Platero; Sandra Carrera-Juliá; María Mar López-Rodríguez; Jose Joaquin Ceron; Asta Tvarijonaviciute; Marí Ángeles Navarro; Mari Luz Moreno; Jose Enrique de la Rubia Ortí
Journal:  Nutrients       Date:  2020-12-10       Impact factor: 5.717

2.  Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients.

Authors:  Shay Menascu; Yulia Khavkin; Rina Zilkha-Falb; Mark Dolev; David Magalashvili; Anat Achiron; Michael Gurevich
Journal:  Ann Clin Transl Neurol       Date:  2020-11-16       Impact factor: 4.511

Review 3.  Outcome measures assisting treatment optimization in multiple sclerosis.

Authors:  Gabriel Pardo; Samantha Coates; Darin T Okuda
Journal:  J Neurol       Date:  2021-08-02       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.